[go: up one dir, main page]

GT200800252A - Derivados de 2-alcoxi-3,4,5-trihidroxi-alquilamida, su preparacion, composiciones que las contienen y utilizacion - Google Patents

Derivados de 2-alcoxi-3,4,5-trihidroxi-alquilamida, su preparacion, composiciones que las contienen y utilizacion

Info

Publication number
GT200800252A
GT200800252A GT200800252A GT200800252A GT200800252A GT 200800252 A GT200800252 A GT 200800252A GT 200800252 A GT200800252 A GT 200800252A GT 200800252 A GT200800252 A GT 200800252A GT 200800252 A GT200800252 A GT 200800252A
Authority
GT
Guatemala
Prior art keywords
trihidroxi
alquilamida
alcoxi
derivatives
compositions
Prior art date
Application number
GT200800252A
Other languages
English (en)
Inventor
Jidong Zhang
Yannick Benedetti
Alain Commercon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200800252A publication Critical patent/GT200800252A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • C07D243/26—Preparation from compounds already containing the benzodiazepine skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS CUYA FÓRMULA GENERAL I EN LA QUE R1,R2,R3,R4,X1,X2,M, SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE. ESTOS COMPUESTOS SON DE UTILIDAD COMO AGENTES ANTICANCERÍGENOS PRINCIPALMENTE PERO TAMBIÉN PUEDEN SER APLICABLES EN CUADROS DE ARTRITIS, OSTEOARTRITIS, INFLAMACIÓN DEL INTESTINO, ENTRE OTRAS PATOLOGIAS DESCRITAS EN EL EXPEDIENTE.
GT200800252A 2006-05-24 2008-11-21 Derivados de 2-alcoxi-3,4,5-trihidroxi-alquilamida, su preparacion, composiciones que las contienen y utilizacion GT200800252A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0604736A FR2901556A1 (fr) 2006-05-24 2006-05-24 Derives de 2-alcoxy-3,4,5-trihydroxy-alkylamide, leur preparation, compositions les contenant et utilisation

Publications (1)

Publication Number Publication Date
GT200800252A true GT200800252A (es) 2009-03-13

Family

ID=37561171

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200800252A GT200800252A (es) 2006-05-24 2008-11-21 Derivados de 2-alcoxi-3,4,5-trihidroxi-alquilamida, su preparacion, composiciones que las contienen y utilizacion

Country Status (24)

Country Link
US (1) US7994161B2 (es)
EP (1) EP2029555A2 (es)
JP (1) JP2009537616A (es)
KR (1) KR20090010215A (es)
CN (1) CN101454296B (es)
AR (1) AR061105A1 (es)
AU (1) AU2007253198A1 (es)
BR (1) BRPI0712264A2 (es)
CA (1) CA2649685A1 (es)
CR (1) CR10390A (es)
DO (1) DOP2007000105A (es)
EA (1) EA200870567A1 (es)
EC (1) ECSP088899A (es)
FR (1) FR2901556A1 (es)
GT (1) GT200800252A (es)
IL (1) IL195053A0 (es)
MA (1) MA30496B1 (es)
MX (1) MX2008015003A (es)
NO (1) NO20085267L (es)
PE (1) PE20080099A1 (es)
TN (1) TNSN08411A1 (es)
TW (1) TW200812981A (es)
UY (1) UY30367A1 (es)
WO (1) WO2007135295A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2878528B1 (fr) 2004-11-29 2008-05-16 Aventis Pharma Sa 2-alcoxy-3,4,5-trihydroxy-alkylamides, leur preparation, compositions les contenant et utilisation
FR2878525B1 (fr) 2004-11-29 2007-02-23 Aventis Pharma Sa Bengamides possedant un cycle caprolactame substitue, procede de preparation, compositions les contenant et utilisation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4477464A (en) * 1983-02-10 1984-10-16 Ciba-Geigy Corporation Hetero-benzazepine derivatives and their pharmaceutical use
US4692522A (en) * 1985-04-01 1987-09-08 Merck & Co., Inc. Benzofused lactams useful as cholecystokinin antagonists
US4831135A (en) * 1986-06-18 1989-05-16 The Regents Of The University Of California Bengamide anthelmintics
US5283241A (en) * 1992-08-28 1994-02-01 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
GB9411841D0 (en) 1994-06-14 1994-08-03 Pharma Mar Sa New antitumoral compounds from jaspis sponge
JP2002241368A (ja) 1997-02-18 2002-08-28 Shionogi & Co Ltd 新規ベンゾラクタム誘導体およびそれを含有する医薬組成物
CO5140099A1 (es) * 1998-11-17 2002-03-22 Novartis Ag Ciertas caprolactamas sustituidas, composiciones farmaceuticas que las contienen, y su uso en el tratamiento de tumores
US6239127B1 (en) * 1999-11-17 2001-05-29 Novartis Ag Certain substituted caprolactams, pharmaceutical compositions containing them and a process for their preparation
CN1191237C (zh) 2000-05-11 2005-03-02 诺瓦提斯公司 取代的己内酰胺碳酸酯与醚和它们作为抗肿瘤剂的用途
EP1337854A2 (en) 2000-11-14 2003-08-27 Novartis AG Method for screening anti-proliferative compounds and inhibiting tumor growth
US6545148B2 (en) * 2001-03-12 2003-04-08 Novartis Ag Process for preparing certain substituted caprolactams
JP2004262793A (ja) 2003-02-28 2004-09-24 Noyaku Bio Technology Kaihatsu Gijutsu Kenkyu Kumiai 化合物ｎ−９０１１、その製造法及び用途
BRPI0412843A (pt) * 2003-07-25 2006-09-26 Novartis Ag lactamas substituìdas e uso das mesmas como agentes anticáncer
US7153846B2 (en) * 2003-10-24 2006-12-26 Sanofi-Aventis Deutschland Gmbh Bengamide derivatives, process for preparing them, and their use
DE10349669B3 (de) 2003-10-24 2005-05-25 Aventis Pharma Deutschland Gmbh Bengamide-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
FR2878525B1 (fr) * 2004-11-29 2007-02-23 Aventis Pharma Sa Bengamides possedant un cycle caprolactame substitue, procede de preparation, compositions les contenant et utilisation
FR2878528B1 (fr) * 2004-11-29 2008-05-16 Aventis Pharma Sa 2-alcoxy-3,4,5-trihydroxy-alkylamides, leur preparation, compositions les contenant et utilisation

Also Published As

Publication number Publication date
MA30496B1 (fr) 2009-06-01
WO2007135295A2 (fr) 2007-11-29
CN101454296A (zh) 2009-06-10
DOP2007000105A (es) 2007-11-15
IL195053A0 (en) 2009-08-03
EA200870567A1 (ru) 2009-06-30
FR2901556A1 (fr) 2007-11-30
US7994161B2 (en) 2011-08-09
PE20080099A1 (es) 2008-03-31
CA2649685A1 (fr) 2007-11-29
NO20085267L (no) 2009-02-23
UY30367A1 (es) 2008-01-02
US20090075971A1 (en) 2009-03-19
MX2008015003A (es) 2008-12-09
ECSP088899A (es) 2008-12-30
CR10390A (es) 2009-01-09
JP2009537616A (ja) 2009-10-29
TW200812981A (en) 2008-03-16
EP2029555A2 (fr) 2009-03-04
KR20090010215A (ko) 2009-01-29
AR061105A1 (es) 2008-08-06
WO2007135295A3 (fr) 2008-01-10
AU2007253198A1 (en) 2007-11-29
TNSN08411A1 (en) 2010-04-14
BRPI0712264A2 (pt) 2012-01-17
CN101454296B (zh) 2011-11-09

Similar Documents

Publication Publication Date Title
GT200600084A (es) Forma cristalina beta de clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen
CL2012000311A1 (es) Compuestos derivados que contiene ciclos con 3 atomos de nitrogeno; utiles en el tratamiento de parasitosis en animales.
CR20150097A (es) Composición inmunogénica
ECSP11010760A (es) Derivados de quinoxalindiona
PA8855001A1 (es) Monocarbamas
UY31198A1 (es) Amidas de ácidos benzoicos triazinil sustituidos, composiciones farmacéticas conteniéndolos y aplicaciones.
GT200300098A (es) Inhibidores de metaloproteinasa de aril-heteroariloxi-ariloxi-pirimidina-2,4,6-triona
UY31138A1 (es) Derivados de indolinonas sustituidas, composiciones conteniendolos y aplicaciones
UY32553A (es) Nuevos derivados de la pirrolidinadiona espiroheterocíclicos 3-sustituidos
UY32010A (es) Nuevas indolinonas, composiciones conteniéndolas y aplicaciones
CR20110381A (es) Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2
CO6341625A2 (es) Derivados de indol como agentes anticáncer
GT200900309A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica
GT200500292A (es) Derivados de 2-amido-4-feniltiazol, su preparacion y su aplicacion en terapeutica
AR064288A1 (es) Fluoresceina sustancialmente pura
ECSP109961A (es) Derivados de indol-2-ona disustituidos en 3, su preparación y su aplicación en terapéutica
CL2010001566A1 (es) Compuesto derivado de piperidinilo, modulador de la actividad de los receptores de la quimiocina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias, alergicas, autoinmune.
DOP2009000214A (es) Macrolidos basados en eritromicina
GT200600072A (es) Composiciones farmaceuticas
GT200800252A (es) Derivados de 2-alcoxi-3,4,5-trihidroxi-alquilamida, su preparacion, composiciones que las contienen y utilizacion
CL2008003928A1 (es) Compuestos derivados de n-6-heterociclo-imidazo-[1,2-a]-piridin-2-carboxamida sustituidos; procedimiento de preparacion; composicion farmaceutica; utiles en el tratamiento y/o prevencion de enfermedades neurodegenerativas, inflamatorias, epilepsia, osteoporosis, tumores malignos, entre otras.
GT200600326A (es) Diazepinoquinolinas, sintesis de las mismas e intermediarios de las mismas
GT200400232A (es) Metodos y composiciones para la inhibicion de selectina
BRPI0603784A (pt) lubrificante pessoal vaporizável
UY29371A1 (es) Pirroles sustituídos, composiciones que los contienen, proceso de fabricación y utilización